Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:10/28/2008

ng developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E. T. Smith, Ph.D.

Vice President, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Webcast Alert: Kaiser Permanente Residency Program Open House
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
9. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
10. Webcast Alert: Heska Announces Third Quarter 2007 Earnings Conference Call Webcast
11. Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
(Date:11/28/2014)... November 28, 2014 An inventor from Flint, ... to day. "I got this idea while lying in a ... bathroom," he said. , The Bed Buddy provides a more ... to the bathroom. It eliminates the need to leave the ... comfort and dignity. Easy to use and producible in design ...
(Date:11/28/2014)... 28, 2014 talklocal ( http://www.talklocal.com ... the right service professionals by phone in about 90 seconds. ... least two tornadoes were reported to have touched down just ... was reported following the tornadoes, Denver residents now know all ... Having TalkLocal is like having local pros in over 50 ...
(Date:11/28/2014)... November 28, 2014 This report ... market along with the definite portrayal of the ... point depiction of various variables driving the development ... difficulties blocking the development of the business. ... , According to the report "Worldwide Dental ...
(Date:11/27/2014)... (PRWEB) November 28, 2014 One ... implant dentistry. The market for implant dentistry comprises ... tools/instruments. The global market for dental care is ... equipments. The dental equipment segment is composed of ... of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The ...
Breaking Medicine News(10 mins):Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... to be more effective than placebos in treating rapid ... study , which included 38 non-schizophrenic, non-bipolar women with ... 51 was conducted by researchers from various universities in ... shift, impulsivity and aggression when given fluvoxamine or a ...
... a national survey of more than 149,000 Americans including 23,000 ... 25% of adults with disabilities, compared to 16 per cent ... defined as having a Body Mass Index greater than 32. ... mobility difficulties and those who had not received exercise counselling ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... in there study are trying to observe why surgery ... ongoing. It's long been known that some older people develop ... - a condition known as Post Operative Cognitive Dysfunction (POCD).Often ... same' as they were before surgery. It was assumed, at ...
... observed that a drug already being used to treat ... male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, which has ... work// as a male contraceptive because it affects the ... tested their theory in an animal study involving mice. ...
... the eye has prevented and stopped autoimmune eye disease in ... treatments for other// autoimmune diseases such as multiple sclerosis and ... Institute in Boston found the factor alpha-MSH can be harnessed ... prevent the onset of and stop the progression of uveitis ...
Cached Medicine News:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... Nov. 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has issued a ... (NDA) for AVP-825. AVP-825 is an investigational drug-device ... intranasally utilizing a novel Breath Powered delivery technology. ... and consistent with the preliminary feedback announced on ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Inc. announced an agreement with the United States Department of ... prescription medication for patients with heart failure. ... plea to a single misdemeanor violation of the Food, Drug ... fine. Scios acknowledges that NATRECOR® was misbranded and ...
... Oct. 5, 2011 SV Life Sciences ("SVLS") today announced the ... joins SVLS with more than 26 years of experience in ... excited to welcome Dr. Dreismann to SVLS," said Lutz Giebel, ... and focus on investments in the diagnostics space. We believe ...
Cached Medicine Technology:SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner 2
Hibbs Retractor with sharp teeth. Used for deep soft tissue retraction....
A general purpose instrument for use around the femur and acetabulum....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The double action wire cutter has both side and end cutting capabilities....
Medicine Products: